Bone mineral density after concurrent chemoradiation in patients with uterine cervical cancer

Menopause

Volumn 17, Issue 2, 2010, Pages 416-420

  Hwang, Jong Ha ^a   Song, Seung Hun ^a   Lee, Jae Kwan ^a   Lee, Nak Woo ^a   Lee, Kyu Wan ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Bone mineral density; Cervical cancer; Concurrent chemoradiation; Menopause

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ADULT; AGE DISTRIBUTION; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BONE DENSITY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROL GROUP; CONTROLLED STUDY; DRUG DOSE REGIMEN; DUAL ENERGY X RAY ABSORPTIOMETRY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FEMUR; HUMAN; HYSTERECTOMY; MEDICAL RECORD; MYOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; POSTMENOPAUSE; SPINE; UTERINE CERVIX CANCER;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BODY MASS INDEX; BONE DENSITY; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; FEMALE; FEMUR; HUMANS; KOREA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RADIATION INJURIES; RISK; SPINE; UTERINE CERVICAL NEOPLASMS;

EID: 77949376791     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181b9b11f     Document Type: Article

References (31)

1. Sekiba K. Use of interceed(TC7) absorbable adhesion barrier to reduce postoperative adhesion reformation in infertility and endometriosis surgery. The Obstetrics and Gynecology Adhesion Prevention Committee. Obstet Gynecol 1992;79:518-522.
2. Michaud LB, Goodin S. Cancer-treatmentYinduced bone loss, part 2. Am J Health Syst Pharm 2006;63:534-546.
3. Cho SH, Lee JA, Moon H, Kim DS. Reduced spinal bone mass in patients with uterine cervical cancer. Obstet Gynecol 1991;78:689-692.
4. Hung YC, Yeh LS, Chang WC, Lin CC, Kao CH. Prospective study of decreased bone mineral density in patients with cervical cancer without bone metastases: a preliminary report. Jpn J Clin Oncol 2002; 32:422-424.
5. Adler RA. Cancer treatmentYinduced bone loss. Curr Opin Endocrinol Diabetes Obes 2007;14:442-445.
6. Brufsky AM. Cancer treatmentYinduced bone loss: pathophysiology and clinical perspectives. Oncologist 2008;13:187-195.
7. Mincey BA. Osteoporosis in women with breast cancer. Curr Oncol Rep 2003;5:53-57.
8. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogen-esis and management. J Clin Oncol 2000;18:1570-1593.
9. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003;88:204-210.
10. Suva LJ, Winslow GA, Wettenhall RE, et al. A parathyroid hormoneY related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987;237:893-896.
11. Strewler GJ, Stern PH, Jacobs JW, et al. Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest 1987;80:1803-1807.
12. Seyberth HW, Segre GV, Morgan JL, Sweetman BJ, Potts JT, Jr, Oates JA. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med 1975;293:1278-1283.
13. Martin TJ, Partridge NC. Prostaglandins, cancer and bone: pharmacological considerations. Metab Bone Dis Relat Res 1980;2:167-171.
14. Sherwin SA, Twardzik DR, Bohn WH, Cockley KD, Todaro GJ. High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res 1983;43:403-407.
15. Mundy GR, Eilon G, Orr W, Spiro TP, Yoneda T. Osteoclast activating factor: its role in myeloma and other types of hypercalcaemia of malignancy. Metab Bone Dis Relat Res 1980;2:173-176.
16. Mundy GR, Ibbotson KJ, D'Souza SM, Simpson EL, Jacobs JW, Martin TJ. The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med 1984;310:1718-1727.
17. Troyer H, Sowers JR, Babich E. Leydig cell tumor induced hyper-calcemia in the Fischer rat: morphometric and histochemical evidence for a humoral factor that activates osteoclasts. Am J Pathol 1982;108: 284-290.
18. Nilas L, Christiansen C. Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest 1988;18:529-534.
19. Elders PJ, Netelenbos JC, Lips P, van Ginkel FC, van der Stelt PF. Accelerated vertebral bone loss in relation to the menopause: a cross-sectional study on lumbar bone density in 286 women of 46 to 55 years of age. Bone Miner 1988;5:11-19.
20. Howland WJ, Loeffler RK, Starchman DE, Johnson RG. Postirradiation atrophic changes of bone and related complications. Radiology 1975; 117:677-685.
21. Oh D, Huh SJ, Nam H, et al. Pelvic insufficiency fracture after pelvic radiotherapy for cervical cancer: analysis of risk factors. Int J Radiat Oncol Biol Phys 2008;70:1183-1188.
22. Mitchell MJ, Logan PM. Radiation-induced changes in bone. Radio-graphics 1998;18:1125-1136; quiz 1242-1243.
23. Bliss P, Parsons CA, Blake PR. Incidence and possible aetiological factors in the development of pelvic insufficiency fractures following radical radiotherapy. Br J Radiol 1996;69:548-554.
24. Bonfiglio M. The pathology of fracture of the femoral neck following irradiation. AJR Am J Roentgenol 1953;70:449-459.
25. Chen HH, Lee BF, Guo HR, Su WR, Chiu NT. Changes in bone mineral density of lumbar spine after pelvic radiotherapy. Radiother Oncol 2002; 62:239-242.
26. Takahashi M, Kushida K, Hoshino H, Ohishi T, Inoue T. Evaluation of bone turnover in postmenopause, vertebral fracture, and hip fracture using biochemical markers for bone formation and resorption. J Endocrinol Invest 1997;20:112-117.
27. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
28. Coleman RE, Major P, Lipton A, et al. Predictive value of bone re-sorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23: 4925-4935.
29. Wehrli FW, Hopkins JA, Hwang SN, Song HK, Snyder PJ, Haddad JG. Cross-sectional study of osteopenia with quantitative MR imaging and bone densitometry. Radiolgy 2000;217:527-538.
30. Shih TT, Chang CJ, Hsu CY, Wei SY, Su KC, Chung HW. Correlation of bone marrow lipid water content with bone mineral density on the lubar spine. Spine 2004;29:2844-2850.
31. Shen W, Chen J, Punyanitya M, Shapses S, Heshka S, Heymsfield SB. MRI-mesasured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. Osteoporos Int 2007;18: 641-647.